Monopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Still a Buy?

Key Points

• Monopar Therapeutics' share price recently reached a new 52-week high of $81.89, with an average target price set at $86.22 by analysts.
• A variety of analysts have issued ratings for the stock, with one giving it a Strong Buy rating and several recommending a "buy" or "overweight" strategy.
• Insiders have sold a total of 592,733 shares in the last quarter, representing significant decreases in their positions within the company.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $81.89 and last traded at $81.67, with a volume of 53412 shares changing hands. The stock had previously closed at $75.90.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MNPR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Raymond James Financial began coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They set a "strong-buy" rating and a $80.00 price target for the company. Piper Sandler set a $95.00 price objective on shares of Monopar Therapeutics and gave the company an "overweight" rating in a report on Thursday, September 25th. Chardan Capital upped their target price on shares of Monopar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a research report on Thursday, September 25th. Finally, Lake Street Capital started coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They set a "buy" rating and a $106.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Monopar Therapeutics has an average rating of "Buy" and an average target price of $86.22.

Monopar Therapeutics Stock Performance

The company has a market cap of $503.90 million, a price-to-earnings ratio of -24.53 and a beta of 1.20. The firm has a fifty day moving average price of $45.05 and a 200 day moving average price of $39.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the director owned 5,173 shares in the company, valued at approximately $206,920. This represents a 76.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares in the company, valued at approximately $17,303,573.86. This trade represents a 66.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 592,733 shares of company stock worth $36,700,227 in the last quarter. Insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MNPR. Police & Firemen s Retirement System of New Jersey bought a new position in Monopar Therapeutics during the 2nd quarter worth $34,000. AlphaQuest LLC bought a new position in Monopar Therapeutics during the 1st quarter worth $44,000. JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Monopar Therapeutics during the 2nd quarter worth $80,000. Finally, New York State Common Retirement Fund bought a new position in Monopar Therapeutics during the 2nd quarter worth $104,000. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.